Lytix Biopharma AS (6BG.F)
- Previous Close
0.4370 - Open
0.4940 - Bid 0.3850 x --
- Ask 0.5080 x --
- Day's Range
0.4940 - 0.4940 - 52 Week Range
0.4080 - 1.1100 - Volume
333 - Avg. Volume
5 - Market Cap (intraday)
19.794M - Beta (5Y Monthly) -0.55
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2100 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, is designed for the local treatment of solid tumors that is in Phase II clinical trials. The company's products comprise of LTX-401, an oncolytic molecule for targeting deep-seated lesions, such as liver cancer and is in a preclinical phase. Lytix Biopharma ASA was incorporated in 2003 and is based in Oslo, Norway.
www.lytixbiopharma.comRelated News
Performance Overview: 6BG.F
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6BG.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6BG.F
Valuation Measures
Market Cap
19.48M
Enterprise Value
12.79M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
58.35
Price/Book (mrq)
3.38
Enterprise Value/Revenue
3.20
Enterprise Value/EBITDA
-0.14
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-56.21%
Return on Equity (ttm)
-94.30%
Revenue (ttm)
10.24M
Net Income Avi to Common (ttm)
-87.94M
Diluted EPS (ttm)
-0.2100
Balance Sheet and Cash Flow
Total Cash (mrq)
50.55M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-67.22M
Company Insights: 6BG.F
6BG.F does not have Company Insights